Octreótido Sandoz (Octreotide Acetate)

Octreotide acetate is a synthetic analogue of somatostatin. It binds to somatostatin receptors, especially SSTR2 and SSTR5, on endocrine and neuroendocrine cells, suppressing the release of growth hormone, insulin, glucagon, and various gastrointestinal peptides, thereby reducing disease‑related hormone activity.

The dosing regimen for Octreótido Sandoz is individualized. A qualified prescriber determines the appropriate dose, frequency, and route (intravenous or subcutaneous) based on the specific indication, patient characteristics, and clinical response.

Safety data for Octreótido Sandoz during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order Octreótido Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Octreótido Sandoz (octreotide) and lanreotide are the two primary somatostatin analogues. Both suppress hormone secretion, but octreotide has a shorter half‑life and is typically administered multiple times daily or via continuous infusion, whereas lanreotide is longer‑acting and often given as a monthly injection. Choice depends on clinical scenario, dosing convenience, and physician preference.

Octreótido Sandoz must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return to refrigeration promptly.

Octreótido Sandoz is supplied as a sterile solution for injection. It can be given intravenously (IV) as a short infusion or subcutaneously (SC) using a syringe. Administration technique, site rotation, and aseptic precautions should follow the prescribing information and institutional protocols.

Serious adverse events include pancreatitis, severe hyperglycemia or hypoglycemia, bradycardia or cardiac arrhythmias, anaphylactic reactions, and hepatic dysfunction. Patients should be monitored for abdominal pain, marked changes in blood glucose, heart rate abnormalities, signs of allergic reaction, and liver enzyme elevations.

Octreótido Sandoz is contraindicated in patients with known hypersensitivity to octreotide acetate or any excipients in the formulation. Caution is advised in individuals with severe cardiac conduction disorders, uncontrolled diabetes, active gallbladder disease, or severe hepatic impairment. The drug should be avoided in these populations unless the prescriber determines that benefits outweigh risks.